Applicant, as named in the Orange Book
Daiichi Sankyo Inc
Next listed expiry: Savaysa on 28 Mar 2028. 3 products with live protection, 0 without.
Products with listed protection
| Drug | Earliest generic entry |
|---|---|
| Savaysa NDA 206316 · 3 strengths edoxaban tosylate | 28 Mar 2028 patent |
| Vanflyta NDA 216993 · 2 strengths quizartinib dihydrochloride | 30 Sep 2033 patent |
| Turalio NDA 211810 pexidartinib hydrochloride | 24 Jul 2038 patent |
Recent events
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.